3.12
-0.09 (-2.96%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Indaptus Therapeutics, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| INDP | - | - | - | 33.86 |
| SONN | 33 M | - | - | 2.07 |
| CDIO | - | - | - | 0.740 |
| REPL | - | - | - | 10.78 |
| ADXN | - | - | - | 1.30 |
| IFRX | - | - | - | 1.09 |
AIStockmoo Score
| Value 35% | -0.8 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -0.8 |
| Timing 35% | 1.3 |
| AI Technical info | NA |
| Technical Oscillators info | 0.5 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -23.9% |
| Pillar Agreement | ×0.87 |
| Not in score | |
| Price Volatility info | -4.5 |
| Final Score | 0.12 |
Select this tab to load the latest available analysis.
|
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 36.87% |
| % Held by Institutions | 13.08% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Sep 2026 | Yahoo Finance |
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%. |
| 13 Aug 2026 | Yahoo Finance |
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate… |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |